5.53
전일 마감가:
$6.03
열려 있는:
$6
하루 거래량:
33,106
Relative Volume:
0.06
시가총액:
$9.52M
수익:
-
순이익/손실:
$-67.28M
주가수익비율:
-0.0584
EPS:
-94.66
순현금흐름:
$-9.80M
1주 성능:
-42.40%
1개월 성능:
+30.12%
6개월 성능:
+0.36%
1년 성능:
-46.47%
Portage Biotech Inc Stock (PRTG) Company Profile
PRTG을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PRTG
Portage Biotech Inc
|
5.53 | 9.52M | 0 | -67.28M | -9.80M | -94.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-07-18 | 재개 | Oppenheimer | Outperform |
2022-03-07 | 개시 | H.C. Wainwright | Buy |
2021-09-21 | 개시 | Oppenheimer | Outperform |
2021-09-02 | 개시 | B. Riley Securities | Buy |
2021-08-19 | 개시 | Cantor Fitzgerald | Overweight |
Portage Biotech Inc 주식(PRTG)의 최신 뉴스
Small Cap Stocks To Add to Your WatchlistMarch 29th - MarketBeat
Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High - Asianet Newsable
Portage Biotech Insider Buyers See Boost After Market Cap Rose US$9.0m - simplywall.st
Promising Biotech Stocks To Watch Now – March 28th - Defense World
Portage Biotech (NASDAQ:PRTG) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Survey - Defense World
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher - Benzinga
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Pre-market Movers: PRTG, RNAZ, PTIX, LGMK... - RTTNews
Portage Biotech (PRTG) Shares Skyrocket In Pre-Hour Trading - Stocks Telegraph
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Portage Biotech Shares Jump Premarket After 'Promising' Preclinical Results in Mesothelioma - Marketscreener.com
Portage Biotech presents preclinical data for PORT-7 - TipRanks
Portage Biotech reports promising mesothelioma treatment data By Investing.com - Investing.com Australia
Portage Reports 'Promising' Preclinical Results in Mesothelioma - MarketScreener
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Portage Biotech Announces Promising Preclinical Results for PORT-7 in Mesothelioma - TipRanks
Portage Biotech Reports Promising Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of Port-7 - MarketScreener
Portage Biotech reports promising mesothelioma treatment data - Investing.com
Portage Biotech stock soars on promising preclinical data - Investing.com
Portage Biotech stock soars on promising preclinical data By Investing.com - Investing.com Canada
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times
Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study - Stock Titan
Portage Biotech Inc. Announces New Director Compensation Plan and Stock Option Grants - TipRanks
Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 - Nasdaq
Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments - Marketscreener.com
Portage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy Approach - TipRanks
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial - The Manila Times
Major Milestone: Portage Biotech's Novel Cancer Drug Enters Final Trial Phase - StockTitan
Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity - MSN
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange - Newsfile
Portage Biotech granted Nasdaq compliance extension By Investing.com - Investing.com Nigeria
Portage Biotech receives extension from Nasdaq to attain listing compliance - MSN
Portage Biotech granted Nasdaq compliance extension - MSN
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements - The Manila Times
Portage Biotech Granted Nasdaq Compliance Extension - TipRanks
Portage Biotech, Inc. Receives Extension to Regain Nasdaq Compliance Following Acceptance of Compliance Plan - Nasdaq
Nasdaq Grants Portage Biotech Critical 18-Month Lifeline to Secure Exchange Status - StockTitan
Hepatocellular Carcinoma Pipeline 2024: Latest FDA Approvals, - openPR
What is the investor’s view on Portage Biotech Inc (PRTG)? - US Post News
Pre-Market Surge: Portage Biotech (PRTG) Sees Upward Movement - Stocks Telegraph
Portage Biotech Announces Completion of $2.15 Million Private Financing - The Manila Times
Portage Biotech Secures $2.15 Million in Private Financing - TipRanks
Portage Biotech, Inc. Completes $2.15 Million Private Placement to Support Corporate Growth - Nasdaq
Insider Confidence: Portage Directors Invest $2.15M in Strategic Private Placement - StockTitan
Portage Biotech (NASDAQ:PRTG) Stock Price Down 7.2% – Here’s What Happened - Defense World
Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc - Marketscreener.com
Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics with New CEO - TipRanks
Portage Biotech Inc (PRTG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):